Conformetrix, a Manchester, UK-based pre-clinical drug discovery company, secured an investment from Aquarius Equity Partners’ Origin Fund.
Established in 2007, Conformetrix provides a platform technology that can determine accurate and biologically-relevant (aqueous) 3D and 4D structures of any small soluble molecule.
This transaction marks the first deal closed by the new Origin Fund, which provides innovative, high growth businesses with equity investments of up to £750k.
FinSMEs
19/11/2009